Zusammenfassung
Die genaue Bestimmung der Betazellmasse (BZM) bei Patienten mit Diabetes mellitus
ist bisher nicht möglich, da Pankreasbiopsien ein nicht vertretbares Risiko mit sich
bringen. Die Entwicklung eines nicht-invasiven Verfahrens wäre deshalb sehr wertvoll,
um die BZM im Laufe der Diabeteserkrankung oder im Rahmen von Interventionsstudien
longitudinal zu erfassen. Dieser Artikel diskutiert die prinzipiellen theoretischen
Anforderungen um dieses Ziel zu erreichen. Zusätzlich gibt er einen Überblick über
Radiopharmazeutika, die in den letzten Jahren als mögliche Tracer evaluiert worden
sind, um die BZM nicht-invasiv in vivo zu bestimmen. Der Artikel diskutiert darüber
hinaus mögliche Perspektiven.
Abstract
Accurate assessment of the beta cell mass in humans is hampered by the inaccessibility
of the pancreas for biopsy sampling. Thus, the development of non-invasive means of
beta cell mass measurement would be invaluable in the study of the natural course
of diabetes and the ongoing trials to preserve beta cell mass in patients with diabetes.
This article discusses the principle theoretical requirements for reaching this goal
and provides an overview of radiopharmaceuticals which have been examined as possible
tracers for non-invasive imaging of the beta cell mass. In addition, some key points
for further developments in this field are discussed.
Schlüsselwörter
Betazellmasse - PET - nicht-invasiv - SUR 1
Key words
beta-cell mass - PET - non-invasive - SUR 1
Literatur
- 1
Weir G C, Bonner-Weir S, Leahy J L.
Islet mass and function in diabetes and transplantation.
Diabetes.
1990;
39
401-415
- 2
Butler A E, Janson J, Bonner-Weir S, Ritzel R, Rizza R A, Butler P C.
β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes.
Diabetes.
2003;
52
102-110
- 3
Stoffers D A, Kieffer T J, Hussain M A et al.
Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain
protein IDX-1 and increase islet size in mouse pancreas.
Diabetes.
2000;
49
741-748
- 4
Mu J, Woods J, Zhou Y P et al.
Chronic inhibition of dipeptidyl peptidase-4 with sitagliptin analog preserves pancreatic
cell mass and function in a rodent model of type 2 diabetes.
Diabetes.
2006;
55
1695-1704
- 5
Sweet I R, Cook D L, Lernmark A, Greenbaum C J, Wallen A R, Marcum E S, Stekhova S A,
Krohn K A.
Systematic screening of potential β-cell imaging agents.
Biochem Biophys Res Commun.
2004;
314
976-983
- 6
Sweet I R, Cook D L, Lernmark A, Greenbaum C J, Krohn K A.
Non-invasive imaging of β-cell mass: A quantitative analysis.
Diabetes Technology & Therapeutics.
2004;
6
652-659
- 7
Hampe C S, Wallen A R, Schlosser M, Ziegler, Sweet I R.
Quantitative evaluation of a monoclonal antibody and its fragment as potential markers
for pancreatic β-cell mass.
Exp Clin Endocrinol Diabetes.
2005;
113
381-387
- 8
Guiot Y, Stevens M, Marhfour I et al.
Morphological localisation of sulfonylurea receptor 1 in endocrine cells of human,
mouse and rat pancreas.
Diabetologia.
2007;
50
1889-1899
- 9
Dubowchik G M, Walker M A.
Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs.
Pharmcol Ther.
1999;
83
67-123
- 10
Moore A, Bonner-Weir S, Weissleder R.
Non-invasive in vivo measurement of β-cell mass in mouse model of diabetes.
Diabetes.
2001;
50
2231-2236
- 11
Ladriere L, Malaisse-Lagae F, Alejandro R, Malaisse W J.
Pancreatic fate of a (125)I-labelled mouse monoclonal antibody directed against pancreatic β-cell surface ganglioside(s)
in control and diabetic rats.
Cell Biochem Funct.
2001;
19
107-115
- 12
Colcher D, Pavlinkova G, Beresford G, Booth B J, Choudhury A, Batra S K.
Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Q J Nucl Med.
1998;
42
225-241
- 13
Malaisse W J.
On the track to the β-cell.
Diabetologia.
2001;
44
393-406
- 14
Malaisse W J, Ladrière L, Cancelas J, Acitores A, Villanueva-Peñacarrillo M L, Valverde I.
Pancreatic and hepatic glycogen content in normoglycemic and hyperglycemic rats.
Mol Cell Biochem.
2001;
219
45-49
- 15
Drucker D J, Nauck M A.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4
inhibitors in type 2 diabetes.
Lancet.
2006;
368
1696-1705
- 16
Reubli J C, Waser B.
Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular
basis for in vivo multireceptor tumour targeting.
Eur J Nucl Med Mol Imaging.
2003;
30
781-793
- 17
Wild D, Béhé M, Wicki A et al.
[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1
(GLP-1) receptor targeting.
J Nucl Med.
2006;
47
2025-2033
- 18
Gotthardt M, Lalyko G, van Eerd-Vismale J et al.
A new technique for in vivo imaging of specific GLP-1 binding sites: First results
in small rodents.
Regul Pept.
2004;
137
162-167
- 19
Ran C, Pantazopoulos P, Medarova Z, Moore A.
Synthesis and testing of β-cell-specific streptozotocin-derived near-infrared imaging
probes.
Angew Chem Int Ed Engl.
2007;
46
8998-9001
- 20
Malaisse W J, Doherty M, Ladrière L, Malaisse-Lagae F.
Pancreatic uptake of [2-(14)C]alloxan.
Int J Mol Med.
2001;
7
311-315
- 21
Malaisse W J, Doherty M, Kadiata M M, Ladriere L, Malaisse-Lagae F.
Pancreatic fate of D-[3H] mannoheptulose.
Cell Biochem Funct.
2001;
19
171-179
- 22
Crenier L, Courtois P, Malaisse W J.
Uptake of tritiated D-mannoheptulose by liver, pancreatic exocrine and endocrine cells.
Int J Mol Med.
2001;
8
155-157
- 23
Lenzen S.
The mechanisms of alloxan- and streptozotocin-induced diabetes.
Diabetologia.
2008;
51
216-226
- 24
Ladriere L, Malaisse-Lagae F, Malaisse W J.
Pancreatic uptake of 65Zn in control and streptozotocin diabetic rats.
Med Sci Res.
2000;
28
43-44
- 25
Schirrmacher R, Weber M, Schmitz A et al.
Radiosyntheses of 1-(4-(2-[18F]fluoroethoxy)benzenesulfonyl)-3-butyl urea: A potential β-cell imaging agent.
J Label Compd Radiopharm.
2002;
45
763-774
- 26
Schneider S, Feilen P J, Schreckenberger M et al.
In vitro and in vivo evaluation of novel glibenclamide derivatives as imaging agents
for the non-invasive assessment of the pancreatic islet cell mass in animals and humans.
Exp Clin Endocrinol Diabetes.
2005;
113
388-395
- 27
Schneider S, Ueberberg S, Korobeynikov A et al.
Synthesis and evaluation of a glibenclamide glucose-conjugate: a potential new lead
compound for substituted glibenclamide derivatives as islet imaging agents.
Regul Pept.
2007;
139
122-127
- 28
Wängler B, Schneider S, Thews O et al.
Synthesis and evaluation of [18F]repaglinide): a promising radioligand for quantification of pancreatic β-cell mass
with positron emission tomography (PET).
Nucl Med Biol.
2004;
31
639-647
- 29
Wängler B, Shiue C Y, Schneider S et al.
Synthesis and in vitro evaluation of (S)-2-([11C]methoxy)-4-([3-methyl-1-(2-piperidine-1-yl-phenyl)-butyl-carbamoyl]-benzoic acid
([11C]methyl-Repaglinide): a potential β-cell imaging agent.
Bioorg Med Chem Lett.
2004;
14
5205-5209
- 30
Maffei A, Liu Z, Witkowski P et al.
Identification of tissue-restricted transcripts in human islets.
Endocrinology.
2004;
145
4513-4521
- 31
Souza F, Simpson N, Raffo A et al.
Longitudinal non-invasive PET-based β-cell mass estimates in a spontaneous diabetes
rat model.
J Clin Invest.
2006;
116
1506-1513
- 32
Liu E H, Herscovitch P, Barker C et al.
C-11-DTBZ PET scanning: Its potential for measuring β-cell mass in vivo.
Diabetes.
2007;
56 Suppl. 1
A 83
- 33
Sweet I R.
Obstacles to achieve adaequate imaging.
Diabetologia.
2007;
50 Suppl. 1
1
- 34
Trepel M, Arap W, Pasqualini R.
In vivo phage display and vascular heterogeneity: implications for targeted medicine.
Curr Opin Chem Biol.
2002;
6
399-404
- 35
Arap W, Kolonin M G, Trepel M et al.
Steps toward mapping the human vasculature by phage display.
Nat Med.
2002;
8
121-127
- 36
Rajotte D, Arap W, Hagerdorn M, Koivunen E, Pasqualini R, Ruoslahti E.
Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display.
J Clin Invest.
1998;
102
430-437
- 37
Samli K N, McGuire M J, Newgard C B, Johnston S A, Brown K C.
Peptide-mediated targeting of the islets of Langerhans.
Diabetes.
2005;
54
2103-2108
Priv. Doz. Dr. med. S. Schneider
Medizinische Klinik 1 · Universitätsklinikum Bergmannsheil · Ruhr-Universität Bochum
Bürkle-de-la-Camp-Platz
44787 Bochum
eMail: Stephan.Schneider@rub.de
